ERBB2 and breast cancer: Additionally, when comparing OS in all three BC subtypes with RRM2B amplifications, ER + PR + HER2 + patients (n = 18) had significantly worse OS than ER- PR- HER2- patients (n = 26) (p = 0.0426).